PIFA PlussPF4™ is a whole blood assay designed to detect or rule-out the presence of antibodies that are the major determinant in the development of Heparin-Induced Thrombocytopenia (HIT). Clinicians get real-time patient data for making time-sensitive anticoagulation decisions.
Sending tests to reference labs often leads to increased turn-around times that are measured in days and higher costs. While clinicians wait for results, patients suspected of having HIT may be taken off Heparin as a precaution and put on more expensive, alternative anticoagulants called Direct Thrombin Inhibitors (DTIs). Many individuals will ultimately test negative for HIT Antibodies and not have a Heparin allergy, but will be exposed to DTIs that are also more difficult to manage and may cause bleeding complications. Help clinicians have the most up-to-date patient information available, before changing therapies. Deliver HIT Antibody results quickly, save money, and avoid unnecessary work.
Ruling out PF4 antibodies rapidly enables clinicians to avoid unnecessary heparin discontinuation and use of alternative anticoagulant therapies, such as Direct Thrombin Inhibitors (DTIs) that can result in:
Ideal for labs of all sizes, PIFA PlussPF4™ offers several advantages:
|PIFA PlussPF4™ Devices (6 tests/pack)||4001101|
|PIFA PlussPF4™ - Controls, 2 Panel (1Pos/1Neg)||4000007|
|PIFA PlussPF4™ - Controls, 10 Panel (5Pos/5Neg)||4000006|